(2-thienyl)glycine | 127663-48-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2-thienyl)glycine
• 英文别名: L-(thien-2-yl)glycine；D-(thien-2-yl)glycine；thien-2-ylglycine；D,L-thien-2-ylglycine；L-(2-thienyl)glycine；D(-)-α-thienylglycine；D-(2-thienyl)glycine；2-D-thienylglycine；thien-2-ylglycin；2-thienylglycin；D,L-2-thienylglycine；2-Thienylaminoacetic acid；2-(thiophen-2-ylamino)acetic acid
• CAS: 127663-48-3
• 化学式: C₆H₇NO₂S
• 分子量: 157.193
• InChiKey: UNQHGXLQKSZYQU-UHFFFAOYSA-N

物化性质

• 沸点：
  383.8±22.0 °C(Predicted)
• 密度：
  1.435±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  77.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (2-thienyl)glycine 生成 N-α-(2-thienyl)glycine methyl ester hydrochloride
  参考文献：
  名称：

  .beta.-thiopropionyl-aminoacid derivatives and their use as

  摘要：

  一种治疗人类或动物细菌感染的方法，包括与β-内酰胺类抗生素联合给药，给予公式(I)的氨基酸衍生物的治疗有效量或其药用可接受的盐、溶剂化合物或体内可水解酯的治疗有效量，其中：R为氢、形成盐的阳离子或体内可水解酯形成基团；R.sub.1为氢、(C.sub.1-6)烷基，可选地被高达三个卤素原子或巯基、(C.sub.1-6)烷氧基、羟基、氨基、硝基、羧基、(C.sub.1-6)烷基羰氧基、(C.sub.1-6)烷氧羰基、甲酰基或(C.sub.1-6)烷基羰基取代，(C.sub.3-7)环烷基，(C.sub.3-7)环烷基(C.sub.2-6)烷基，(C.sub.2-6)烯基，(C.sub.2-6)炔基，芳基，芳基(C.sub.1-6)烷基，杂环烷基或杂环烷基(C.sub.1-6)烷基；R.sub.2为氢，(C.sub.1-6)烷基或芳基(C.sub.1-6)烷基；R.sub.3为氢，(C.sub.1-6)烷基，可选地被高达三个卤素原子取代，(C.sub.3-7)环烷基，融合的芳基(C.sub.3-7)环烷基，(C.sub.3-7)环烷基(C.sub.2-6)烷基，(C.sub.2-6)烯基，(C.sub.2-6)炔基，芳基，芳基-(CHR.sub.10).sub.m --X--(CHR.sub.11).sub.n，杂环烷基或杂环烷基-(CHR.sub.10).sub.m --X--(CHR.sub.11).sub.n，其中m为0至3，n为1至3，每个R.sub.10和R.sub.11独立地为氢或(C.sub.1-4)烷基，X为O，S(O).sub.x，其中x为0-2，或键；R.sub.4为氢，或体内可水解的酰基；R.sub.5和R.sub.6独立地为氢和(C.sub.1-6)烷基，或一起代表(CH.sub.2).sub.p，其中p为2至5。一些化合物本身被要求。

  公开号：

  US06048852A1

文献信息

• Inhibitors of cathepsin S
  申请人：IRM LLC

  公开号：US20040198780A1

  公开（公告）日：2004-10-07

  The present invention provides compounds, compositions and methods for the selective inhibition of cathepsin S. In a preferred aspect, cathepsin S is selectively inhibited in the presence of at least one other cathepsin isozyme (e.g., cathespin K). The present invention also provides methods for treating a disease state in a subject by selectively inhibiting cathepsin S.

  本发明提供了用于选择性抑制蛋白酶S的化合物、组合物和方法。在一个优选方面，当至少存在另一种蛋白酶同工酶（例如，蛋白酶K）时，选择性地抑制蛋白酶S。本发明还提供了通过选择性抑制蛋白酶S来治疗受试者疾病状态的方法。
• Composition for preventing or treating ischemic disease
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP0950418A2

  公开（公告）日：1999-10-20

  The present invention is to provide a pharmaceutical composition for preventing or treating ischemic disease comprising a compound having endothelin antagonistic activity or a salt thereof in combination with a compound having activity for inhibiting Na-H exchange or a salt thereof, which shows remarkable prophylactic or therapeutic effect on ischemic disease and which serves to decrease remarkably the dosage of the individual effective components, and as a result, suppresses undesirable side effects observed in the case of administering the respective compounds singly.

  本发明旨在提供一种用于预防或治疗缺血性疾病的药物组合物，该组合物包含具有内皮素拮抗活性的化合物或其盐，以及具有抑制Na-H交换活性的化合物或其盐，该组合物对缺血性疾病显示出显著的预防或治疗效果，并且显著降低了个别有效成分的剂量，因此，压制了在单独给药时观察到的令人不快的副作用。
• Cycloalkylcarbonylamino Acid Ester Derivative and Process for Producing The Same
  申请人：Kobayashi Nobuo

  公开号：US20090137799A1

  公开（公告）日：2009-05-28

  Cycloalkylcarbonylamino acid ester derivatives, which are raw material intermediates for a novel cycloalkane carboxamide derivative having an action that selectively inhibits cathepsin K, and a production process thereof, are provided. A cycloalkylcarbonylamino acid ester derivative represented by formula (I), or a pharmaceutically acceptable salt thereof: (wherein, R 1 and R 2 represent alkyl groups, alkenyl groups, alkynyl groups, aromatic hydrocarbon groups, heterocyclic groups, etc., R 8 represents an alkyl group having 1 to 6 carbon atoms, and ring A represents a cyclic alkylidene group having 5, 6 or 7 carbon atoms).

  环烷基羰基氨基酸酯衍生物是一种新型环烷烃羧酰胺衍生物的原料中间体，具有选择性抑制卡特普辛K的作用，提供其生产工艺。 表示为式（I）的环烷基羰基氨基酸酯衍生物，或其药学上可接受的盐： （其中，R1和R2代表烷基、烯基、炔基、芳香烃基、杂环基等，R8代表具有1至6个碳原子的烷基，环A代表具有5、6或7个碳原子的环烷基亚基）。
• (Carbamoyl)pyridino derivatives of ureidocephalosporins
  申请人：E. R. Squibb & Sons, Inc.

  公开号：US04024135A1

  公开（公告）日：1977-05-17

  Ureido cephalosporin derivatives of the formula ##STR1## wherein R.sub.1 is hydrogen or methoxy; R.sub.2 is hydrogen or lower alkyl; R.sub.3 is hydrogen, lower alkyl, cycloalkyl, cycloalkenyl, cycloalkadienyl, phenyl, phenyl-lower alkyl, substituted phenyl, substituted phenyl-lower alkyl; or certain heterocyclic groups; are disclosed. These compounds are useful as antibacterial agents.

  尿嘧啶头孢菌素衍生物的化学式为##STR1##其中R.sub.1为氢或甲氧基；R.sub.2为氢或较低烷基；R.sub.3为氢、较低烷基、环烷基、环烯基、环二烯基、苯基、苯基-较低烷基、取代苯基、取代苯基-较低烷基；或某些杂环基团；这些化合物可用作抗菌剂。
• 3-Triazolylthio derivatives of ureido cephalosporins
  申请人：E. R. Squibb & Sons, Inc.

  公开号：US03996217A1

  公开（公告）日：1976-12-07

  Ureido cephalosporin derivatives of the formula ##STR1## wherein R is hydrogen, lower alkyl, phenyl-lower alkyl, diphenyllower alkyl, tri(lower alkyl)silyl, trihaloethyl, a salt forming ion, or the group ##STR2## R.sub.1 is hydrogen, lower alkyl, cycloalkyl, cycloalkenyl, cycloalkadienyl, phenyl, phenyl-lower alkyl, substituted phenyl or phenyl-lower alkyl, or certain heterocyclic groups; R.sub.2 is hydrogen or lower alkyl; R.sub.3 is hydrogen or methoxy; R.sub.4 is triazolyl or substituted triazolyl; R.sub.5 is hydrogen or lower alkyl; R.sub.6 is lower alkyl, phenyl, or phenyl-lower alkyl; are disclosed. These compounds are useful as antibacterial agents.

  尿嘧啶头孢菌素衍生物的化学式为##STR1##其中R为氢、较低烷基、苯基较低烷基、二苯基较低烷基、三(较低烷基)硅基、三卤乙基、盐形成离子，或基团##STR2##R.sub.1为氢、较低烷基、环烷基、环烯基、环烷二烯基、苯基、苯基较低烷基、取代苯基或苯基较低烷基，或某些杂环基团；R.sub.2为氢或较低烷基；R.sub.3为氢或甲氧基；R.sub.4为三唑基或取代三唑基；R.sub.5为氢或较低烷基；R.sub.6为较低烷基、苯基或苯基较低烷基。这些化合物可用作抗菌剂。